Substance having an effect on the body
POPULARITY
Categories
147 episodes with Drug
157 episodes with Drug
109 episodes with Drug
170 episodes with Drug
77 episodes with Drug
155 episodes with Drug
61 episodes with Drug
98 episodes with Drug
70 episodes with Drug
57 episodes with Drug
64 episodes with Drug
35 episodes with Drug
190 episodes with Drug
45 episodes with Drug
33 episodes with Drug
24 episodes with Drug
126 episodes with Drug
23 episodes with Drug
33 episodes with Drug
28 episodes with Drug
77 episodes with Drug
52 episodes with Drug
28 episodes with Drug
23 episodes with Drug
51 episodes with Drug
44 episodes with Drug
62 episodes with Drug
49 episodes with Drug
22 episodes with Drug
20 episodes with Drug
26 episodes with Drug
41 episodes with Drug
31 episodes with Drug
51 episodes with Drug
29 episodes with Drug
46 episodes with Drug
51 episodes with Drug
17 episodes with Drug
19 episodes with Drug
12 episodes with Drug
13 episodes with Drug
18 episodes with Drug
16 episodes with Drug
17 episodes with Drug
16 episodes with Drug
18 episodes with Drug
20 episodes with Drug
30 episodes with Drug
17 episodes with Drug
30 episodes with Drug
24 episodes with Drug
16 episodes with Drug
15 episodes with Drug
26 episodes with Drug
In this episode of The Performance Medicine Show, Dr. Rogers answers YOUR health and wellness questions! Check out our online vitamin store: https://performancemedicine.net/shop/Sign up for our weekly newsletter: https://performancemedicine.net/doctors-note-sign-up/
In this week's Stansberry Investor Hour, Dan and John Engel welcome Dave Lashmet to the show. Dave is the editor of Stansberry Venture Technology, an advisory that takes a "venture capitalist" look at the market. Dave scours the market looking for little-known small-cap companies that are potentially producing the next wonder drug or technology. Dave kicks things off by discussing the first of three biopharmaceutical companies he's sharing that have monopolies in weight-loss drugs. He starts by showing how drugs gain their monopolies via patents, giving them "economic exclusivity." While companies might be targeting the same patients, the patents influence how they're being treated. The first company gains an edge by not only targeting folks suffering from obesity, but also by treating those with Type 2 diabetes. Dave also explains the contrast in mentality between the U.S. and other countries regarding obesity being preventable. And he provides info showing how obesity is a "slippery slope" and shares that a study found that participants who got off the drug gained back the weight they lost before. (0:00) Next, Dave sums up how the first company has cleared all of the risks and expenses from clinical trials, while a close competitor still has to get past its trials due to unknown side effects. When asked about why folks would stay on a weight-loss pill for life, Dave points to how our culture has drastically changed over the years, from actively working on farms to passively working in cubicles. These drugs help balance out the resulting shift. Dave then transitions into the next company that has a drug that focuses on fatty liver disease. He explains how this distinction helps the company gain its monopoly due to how irreplaceable livers are. And similar to the first company, this drug will have lifelong consumers. And the good news for investors is that its only competitor causes weight gain. (21:49) Finally, Dave presents the final company that tackles weight loss by focusing on genetics. Unlike the first two companies, this one treats patients with an injectable drug rather than a pill. However, it zeroes in on our natural "hunger switch," suppressing the users' appetites. Right now, the company is only waiting to get past trials, which puts it at a disadvantage compared with the other two. But Dave still believes that because of how it works, it's still set to stand beside the two pills. (39:44)
RevitalyzeMD - RMD Podcast: All things Aesthetics & Wellness
Welcome to the Atomic Anesthesia podcast hosted by CRNA professor Dr. Rhea Temmermand and Co-Founder Sachi Lord. On this show, you'll hear clear, clinically grounded discussions designed for nurse anesthesia residents and CRNAs who want to feel more confident in complex pharmacology, physiology, and real-world anesthesia decision-making.⚠️ SIGN UP FOR OUR FREE NEWSLETTER: [NEWSLETTER SIGN-UP]In this episode:One-week launch countdown plus a behind-the-scenes tour of the new Atomic Anesthesia platform.Overview of current features: 150+ lessons, quiz builder with 2,000+ questions, and gamified learning with avatars, gems, and leaderboards.Breakdown of seven core pharmacology concepts to make drug questions predictable instead of pure memorization.Clinical-style thinking tips: using receptor logic, dose–response, onset, redistribution, protein binding, and context-sensitive half-time to anticipate drug behavior.
Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USOne on One Video Call W/George https://tidycal.com/georgepmonty/60-minute-meetingI found footage of two octopi speaking in geometric patterns. Ran it throughlinguistic software. It flagged as LANGUAGE—the same patterns I'd been seeingon DMT for years. So I reverse-engineered their neurochemistry, attached it toa tryptamine, and learned to read the language my hallucinations have beenspeaking this entire time.LEXICON-7: the compound that hijacks your claustrum and teaches you exponentiallanguage. The mandalas aren't decoration—they're grammar. The geometry isn'tnoise—it's syntax. Seven dimensions. Cross-modal binding. Visual cortex wireddirectly to Broca's area.I took it in an art studio. The paintings started conjugating.I learned to respond.Now I can't stop reading. The world is written in a language I finallyunderstand, and it's beautiful and terrifying in exactly equal measure.Octopi have been doing this for 300 million years. Now, theoretically, so canyou.◯ ⟲ ⟲ ⟲ — One on One Video call W/George https://tidycal.com/georgepmonty/60-minute-meetingSupport the show:https://www.paypal.me/Truelifepodcast?locale.x=en_US
Along with no alcohol and no drugs, young people making their Confirmation pledges will now promise not to vape until they're 18 years old. For more on this Anton spoke to Bishop Michael Router of the Irish Bishop's Drug's.
Along with no alcohol and no drugs, young people making their Confirmation pledges will now promise not to vape until they're 18 years old. For more on this Anton spoke to Bishop Michael Router of the Irish Bishop's Drug's.
British Columbia's drug decriminalization pilot has officially come to an end, with the province acknowledging it did not deliver the results hoped for. The search for Nancy Guthrie in the US is continuing with investigators still following leads and hoping for answers. For families, friends, and communities, every day without resolution brings uncertainty and heartbreak. Canada's much‑watched electric vehicle rebate program is back... but while the new system offers up to $5,000 toward the purchase of a new EV, issues from the old program are still causing headaches for some dealers. Learn more about your ad choices. Visit megaphone.fm/adchoices
See omnystudio.com/listener for privacy information.
Investigative reporter Nick McKenzie’s 2024 exposé of the criminal infiltration of the construction sector prompted a slew of investigations among governments and law enforcement agencies around the country.The conclusions of those investigations reveal the extent of that corruption, and its findings are damning - including that the CFMEU's conduct could have cost taxpayers $15 billion, and the Victorian government knew of the problems but did not fix the problem.Drug trafficking and shocking sexual exploitation of women on major infrastructure sites - are some of the other claims.Today Nick McKenzie on the serious questions the government has to answer.Subscribe to The Age & SMH: https://subscribe.smh.com.au/See omnystudio.com/listener for privacy information.
Investigative reporter Nick McKenzie’s 2024 exposé of the criminal infiltration of the construction sector prompted a slew of investigations among governments and law enforcement agencies around the country.The conclusions of those investigations reveal the extent of that corruption, and its findings are damning - including that the CFMEU's conduct could have cost taxpayers $15 billion, and the Victorian government knew of the problems but did not fix the problem.Drug trafficking and shocking sexual exploitation of women on major infrastructure sites - are some of the other claims.Today Nick McKenzie on the serious questions the government has to answer.Subscribe to The Age & SMH: https://subscribe.smh.com.au/See omnystudio.com/listener for privacy information.
In this episode, Alex Yampolsky, PharmD MBA, Chief Clinical Officer at MedServe, discusses how outdated medication management puts outpatient facilities at risk and how technology can prevent drug diversion, improve safety, and reduce administrative burden. He also shares career lessons from his path as a pharmacist turned healthcare entrepreneur.
The 23rd Big Sky Documentary Film Festival is underway in Missoula. The annual event celebrates nonfiction films and creators from around the world – including right here in Montana. MTPR's Austin Amestoy sat down with the filmmakers behind “Big Sky Falling,” a film about a web of Montana State University student athletes connected to a killing and drug dealing ring.
Send a text | I am your host, Neo Griot, and this is Episode 269 of the Rational Black Thought Podcast. This week's title is a line Kanye dropped that still cuts like a scalpel: “Drug dealer buy Jordans, crackhead buy crack / And a white man get paid off of all of that.” From “All Falls Down” on College Dropout. And I'm starting there because it's not just a lyric. It's a diagnosis. It's the economic machine in plain English: predation gets dressed up as “the market,” addiction gets criminalized, consumption gets celebrated, and the profits flow upward to people who never touch the poison. The street-level players get cages. The executives get quarterly bonuses. And everybody pretends this is just “personal responsibility” instead of a system engineered for extraction. So that's the moral frame for today's episode: follow the incentives, follow the money, and don't let anyone replace analysis with fucking sermons. Intro: Quote of the Week: James Baldwin Unmasking the News: Democracy Watch: Bondi in Two Chambers: Same Shit“Energy Freedom” or Freedom From Accountability Seven Years for a Pastor Who Preyed on a Teen Isn't Justice. It's Barely a Slap on the Wrist Good News: David Steward Didn't Go Viral. He Went Vertical Bible Study with an Atheist: From Spirits to Sky-Daddies: How Religion Evolved When Humans Didn't Know What Was Going On Reflections and Call to Action: Closing/Outro:https://www.courthousenews.com/gop-leaders-split-on-bondis-use-of-lawmaker-epstein-files-search-history/https://apnews.com/article/green-energy-environment-trump-rollbacks-fact-check-208382e5fb17f9ec6831831f50f7232ehttps://www.theguardian.com/us-news/2026/feb/12/louisiana-pentecostal-pastor-molestation-sentencehttps://www.thetallcotton.com/david-l-steward-world-wide-technology/Power Concedes Nothing without a Demand...
An advisory panel to Japan's health minister decided Friday to allow public health insurance coverage for a gene therapy for muscular dystrophy beginning Feb. 20 and set the drug's official price at about 304.97 million yen. Elevidys, a one-time treatment for Duchenne muscular dystrophy in ambulatory patients aged 3-7, will become the country's most expensive drug. Episode notes: ‘Japan Approves Muscular Dystrophy Drug Price of 300 M. Yen': https://barrierfreejapan.com/2026/02/14/japan-approves-muscular-dystrophy-drug-price-of-300-m-yen/
The science says no, at least not in the athletic sense. But the psychic benefits can be large — just ask former N.F.L. star Ricky Williams. He says athletes should consider cannabis a healing drug, not a party drug. Even the N.F.L. is starting to agree. (Part two of a two-part series.) SOURCES:Angela Bryan, professor, associate chair for faculty development in the department of psychology and neuroscience at the University of Colorado, Boulder.Ricky Williams, former N.F.L. running back, founder of Highsman. RESOURCES:"Using A Lab On Wheels To Study Weed From Dispensaries," by Science Friday (2024)."Exercise-induced euphoria and anxiolysis do not depend on endogenous opioids in humans," by Michael Siebers, Sarah Biedermann, Laura Bindila, Beat Lutz, and Johannes Fuss (Psychoneuroendocrinology, 2021)."Endocannabinoids mediate runner's high," by Sudhakaran Prabakaran (Science Signaling, 2015)."Cannabis and Exercise Science: A Commentary on Existing Studies and Suggestions for Future Directions," by Angela Bryan, Arielle Gilman, and Kent Hutchison (Sports Medicine, 2015).Run Ricky Run, documentary (2010). EXTRAS:"Is America Switching from Booze to Weed?" series by Freakonomics Radio (2024). Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the US Food and Drug Administration's controversial decision to refuse to file Moderna's mRNA-1010 seasonal influenza vaccine candidate, including the unusual public airing of grievances (2:10), the changing issues sparking RTF actions (5:51), the uncertainty created by the decision and how vaccine sponsors should react going forward (16:54). More On These Topics From The Pink Sheet Moderna Cites Changing Advice As US FDA Refuses To File Flu Vaccine BLA: https://insights.citeline.com/pink-sheet/vaccines/moderna-cites-changing-advice-as-us-fda-refuses-to-file-flu-vaccine-bla-SRLIEHHMOFEWFPTLYJCXFIF5FM/ HHS Defends US FDA Refusal To File Moderna's Flu Vaccine: https://insights.citeline.com/pink-sheet/vaccines/hhs-defends-us-fda-refusal-to-file-modernas-flu-vaccine-NULTQ6P6R5C6DDXZFMZROE3HRU/
⭐ This is a featured encore of one of our most downloaded STR Investing episodes. Originally released on June 6th 2024, this episode continues to inspire investors to think bigger and execute smarter.In this episode of the STR Investing Podcast, co-host Taylor Jones welcomes Tyann Marcink, the "Queen of Guest Experience," to share how she transformed a $55,000 drug house into a $1.5 million short-term rental success story.Tyann walks through: • How she identified hidden potential others overlooked • The renovation strategy that unlocked massive value • The guest experience upgrades that drive revenue • Lessons learned from turning a distressed property into a high-performing assetThis episode proves that creative vision, execution, and guest-focused design can completely change the trajectory of a deal.If you're serious about scaling your short-term rental portfolio, this is one to study.__Episode Sponsored By:STR SearchSTR Search is the industry leading property finder service. They've helped investors acquire over 215 profitable STRs across the US. If you'd like the data professionals to help you find your next STR, reach out to STRsearch.com
Scientists at Dublin City University (DCU, Ireland), in collaboration with research teams in Chimie ParisTech – PSL (France), Chalmers University of Technology, Sahlgrenska University Hospital, Gothenburg (Sweden), and the University of Limerick (Ireland), have developed a new chemical strategy for designing metal-based compounds capable of damaging cancer cell DNA, offering a potential new direction for future anticancer drug development. Led by Professor Andrew Kellett, this European consortium has created a series of molecules that cut DNA through a distinct chemical mechanism compared with existing chemotherapy drugs. The research focuses on early-stage compounds that could form the basis of future therapies, particularly in cancers that become resistant to treatment. The scientists used click chemistry—a fast and reliable method for assembling molecular components—to create a family of compounds known as Tri-Click ligands. When combined with copper ions, these ligands form artificial metallo-nucleases, metal-containing agents designed to cleave DNA. Drug resistance remains one of the biggest challenges in cancer treatment. Tumours can adapt by repairing specific forms of DNA damage or by blocking the activity of conventional drugs. A key advantage of this new chemical strategy is that the compounds damage DNA via pathways that differ from those targeted by many current cancer treatments. This means they may avoid some of the typical mechanisms that cancers use to become resistant. Professor Andrew Kellett, Professor of Inorganic and Medicinal Chemistry at DCU, said: "Click chemistry has transformed how we build complex molecules, but its potential as a platform to assemble DNA-damaging chemotherapeutics is underexplored. One of the major challenges in cancer treatment is drug resistance. By developing compounds that damage DNA in a different way, we aim to open up new possibilities for overcoming some of the limitations of existing therapies. While this research is still at an early stage, it provides a valuable platform for future drug development." Professor Gilles Gasser, Professor of Bioinorganic Chemistry at Chimie ParisTech, said: "This work is clear evidence of the potential of metal-based compounds for anticancer research, going beyond the currently heavily used platinum-based drugs. While still in its infancy, this study is a first step towards new solutions for cancer treatment. On a completely different note, this work is another demonstration of the power of collaboration between European scientists and institutions." Professor Damien Thompson, Director of SSPC, the Research Ireland Centre for Pharmaceuticals & Professor of Molecular Modelling at UL, said: "This work exemplifies the value of systematic, deep screening of molecular properties in the development of more effective medicines. Support from SSPC, the Research Ireland Centre for Pharmaceuticals, enabled strong collaboration between our experimental and modelling teams, and this new design strategy marks a key milestone in developing sustainable, well-tolerated anticancer drugs." Professor Fredrik Westerlund, Professor of Molecular Bioscience at Chalmers University of Technology, said: "This study truly highlights how combined expertise across Europe can lead to innovative results in a research field of paramount importance. Novel treatments to resistant cancer tumours are highly desired in the clinics, and the metal compounds developed in this study have many of the properties that are eagerly sought for." The findings are published in the journal Nature Communications: https://www.nature.com/articles/s41467-026-68911-5 The researchers emphasise that the findings are preclinical, and further testing is required before any potential clinical application. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe ...
This seems like a trap.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Driver accused of intentionally hitting group outside a California Safeway including Little Leaguers selling beef jerky , Olympic athlete wins bronze medal and then publicly shames himself for cheating on his girlfriend, Drug dealer who was inspired by 'Home Alone' rigged his house with booby traps
-Rob reacts in horror as on-the-ground footage shows California's “homeless industrial complex” reviving fentanyl users with Narcan—only to hand them fresh needles so the cycle can continue. -Hilary Fordwich, joining via the Newsmax Hotline, breaks down how the Epstein fallout rattles the British royal family, sidelines Prince Andrew, and puts Prime Minister Keir Starmer in a political lose-lose as Prince William quietly cleans house. Today's podcast is sponsored by : RELIEF FACTOR - You don't need to live with aches & pains! Reduce muscle & joint inflammation and live a pain-free life by visiting http://ReliefFactor.com QUINCE CLOTHING - Refresh your wardrobe with Quince. Go to http://Quince.com/NEWSMAX for free shipping on your order and 365-day returns. BIRCH GOLD - Protect and grow your retirement savings with gold. Text ROB to 98 98 98 for your FREE information kit! To call in and speak with Rob Carson live on the show, dial 1-800-922-6680 between the hours of 12 Noon and 3:00 pm Eastern Time Monday through Friday…E-mail Rob Carson at : RobCarsonShow@gmail.com Musical parodies provided by Jim Gossett (http://patreon.com/JimGossettComedy) Listen to Newsmax LIVE and see our entire podcast lineup at http://Newsmax.com/Listen Make the switch to NEWSMAX today! Get your 15 day free trial of NEWSMAX+ at http://NewsmaxPlus.com Looking for NEWSMAX caps, tees, mugs & more? Check out the Newsmax merchandise shop at : http://nws.mx/shop Follow NEWSMAX on Social Media: -Facebook: http://nws.mx/FB -X/Twitter: http://nws.mx/twitter -Instagram: http://nws.mx/IG -YouTube: https://youtube.com/NewsmaxTV -Rumble: https://rumble.com/c/NewsmaxTV -TRUTH Social: https://truthsocial.com/@NEWSMAX -GETTR: https://gettr.com/user/newsmax -Threads: http://threads.net/@NEWSMAX -Telegram: http://t.me/newsmax -BlueSky: https://bsky.app/profile/newsmax.com -Parler: http://app.parler.com/newsmax Learn more about your ad choices. Visit megaphone.fm/adchoices
This seems like a trap. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
With a carnivore diet, Phillip improved over 30 years of skin issues including eczema, severe plaque psoriasis, palm and plantar psoriasis, and scalp psoriasis. Phillip also improved his pre-diabetes. Instagram: https://www.instagram.com/mrphillipwin/ TikTok: https://www.tiktok.com/@mrphillipwin X: https://x.com/MrPhillipWin Timestamps: 00:00 Diet's role in autoimmune health 04:49 Topical steroid concerns in dermatology 09:49 Medication concerns and side effects 12:43 Psoriasis treatment self-discovery 14:49 Persistence with psoriasis treatment 17:49 Carnivore diet benefits and downsides 20:19 Health concerns and cultural food 24:02 Dairy tolerance and eczema 29:28 Biologics push for psoriasis treatment 31:11 Drug cycle and muscle loss 35:01Overcoming chronic illness Join Revero now to regain your health: https://revero.com/YT Revero.com is an online medical clinic for treating chronic diseases with this root-cause approach of nutrition therapy. You can get access to medical providers, personalized nutrition therapy, biomarker tracking, lab testing, ongoing clinical care, and daily coaching. You will also learn everything you need with educational videos, hundreds of recipes, and articles to make this easy for you. Join the Revero team (medical providers, etc): https://revero.com/jobs #Revero #ReveroHealth #shawnbaker #Carnivorediet #MeatHeals #AnimalBased #ZeroCarb #DietCoach #FatAdapted #Carnivore #sugarfree Disclaimer: The content on this channel is not medical advice. Please consult your healthcare provider.
What would you do if your pharmacist came to you and said "I'd like to get a plan together to get you on less medication?" That's what host Steve Cutler and guest Brian Lunt discuss in Episode 185 of The Evolved Man. Utilizing therapeutic lifestyle changes along with medication Brian and his team are making headways in the healthcare space. Join Steve and Brian for a conversation about how therapeutic lifestyle changes can significantly reduce your need for medication and how having a collaborative conversation with your health care providers can move you in a positive way towards better health and healing. Connect with Brian HERE Follow Us! Newsletter Instagram X The Evolved Man is produced by Steve Cutler and EVOLVE International, LLC, all rights reserved. This podcast is for entertainment purposes only. Always consult with a qualified medical professional before starting, changing or adjusting any exercise, health or nutrition protocols.
Synopsis: At JPM 2026 in San Francisco, Alok Tayi welcomes Michelle Werner, CEO of Alltrna, to Biotech 2050 for a powerful conversation at the intersection of personal mission, platform biology, and rare-disease drug development. Michelle traces her two-decade career across Bristol Myers Squibb, AstraZeneca, and Novartis—and the moment everything changed when her child was diagnosed with a rare disease. That experience led her to Alltrna and its pioneering engineered tRNA platform, designed to correct nonsense mutations across hundreds—potentially thousands—of genetic disorders with a single therapeutic approach. Together, Alok and Michelle explore how tRNAs work, why “stop-codon disease” could redefine rare-disease classification, and how basket trials borrowed from oncology may accelerate development. They dive into delivery strategy, portfolio expansion into CNS and muscle disorders, regulatory innovation, and how AI is reshaping molecular design—offering a rare look at what it takes to build a first-in-class modality from the ground up. Biography: Michelle is a seasoned pharmaceutical executive with more than 20 years in the industry spanning commercial and research & development (R&D) responsibilities. Prior to Alltrna, Michelle served as Worldwide Franchise Head, Solid Tumors at Novartis Oncology, where she was responsible for delivering the disease area strategies across multiple tumors and led business development efforts resulting in a doubling of long-term portfolio value for the franchise. Previous to Novartis, Michelle was a senior leader at AstraZeneca and as Global Franchise Head in Hematology, she was critical in launching multiple indications worldwide for CALQUENCE®. Prior to this, Michelle was Head of US Oncology, where she led the business through dramatic growth in both team and revenue through eight-plus product launches. Previous to AstraZeneca, Michelle was with Bristol-Myers Squibb for 10 years in various positions of increasing responsibility including roles in sales, marketing, and market access in the US and UK, and above market in Europe (based in France) and global almost exclusively in oncology. Michelle started her professional career in R&D, working hands-on with patients at the Oncology Clinical Trials Unit at Harvard Medical School before moving into industry in clinical operations. Outside of her corporate responsibilities, Michelle is a wife and mother to three children and is a member of the rare disease community. She is currently serving a Board appointment for the non-profit organization Rare Disease Renegades, a purpose that fuels her passions both personally and professionally.
“I suspect that RNAi-based medicines will approach, rival, maybe even exceed what we’ve seen with monoclonal antibodies historically,” says John Maraganore, the CEO of JMM Innovations and founding CEO of Alnylam. He joins Bloomberg Intelligence’s senior pharmaceutical analyst Sam Fazeli to reflect on RNAi’s journey from scientific curiosity to durable drug platform. Maraganore explains Alnylam’s reliance on big pharma partnerships for relatively non-dilutive capital, why rare diseases were the right entry point for commercialization and how mission-first culture sustained the company. He also discusses biotech’s “Sputnik moment,” FDA efficiency and where AI is already delivering real impact in drug discovery.See omnystudio.com/listener for privacy information.
The rising cost of drugs in 2025 was driven by several factors, including inflation, supply chain issues, and the demand for specialty drugs – straining already overburdened health systems. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jeff Harper, head of product at IntelliGuard, about these pressing issues and what hospitals can expect as we progress further into 2026. The conversation also explores the role digital health technologies like RFID and predictive analytics could play in addressing drug waste and ensuring access, as well as why hospital CFOs and pharmacy leaders are reframing medication management as a strategic priority, not just an operational one You can listen to episode 244 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
Britain and China both saw the opium crisis clearly enough to know it would end in disaster. Each believed it understood the situation, and the other, well enough to keep events from spinning out of control. And yet... it happened anyway.Time Period Covered:Late 1839 – April 1840 Major Historical Figures: The Qing Empire:The Daoguang Emperor (Aisin-Gioro Minning) [r. 1820–1850]Lin Zexu, Imperial Commissioner and Governor-General of Huguang [1785–1850] The British Empire:Queen Victoria [r. 1837–1901]Henry John Temple, 3rd Viscount Palmerston, Foreign Secretary [1784–1865]Charles Elliot, Chief Superintendent of British Trade in China [1801–1875]William Gladstone, Member of Parliament [1789–1898]Sir James Graham, Member of Parliament [1792–1861] Major Sources Cited:Platt, Stephen R. Imperial Twilight: The Opium War and the End of China's Last Golden AgeLovell, Julia. The Opium War: Drugs, Dreams and the Making of ChinaFairbank, John K. Trade and Diplomacy on the China CoastHansard's Parliamentary Debates, 1840 Learn more about your ad choices. Visit megaphone.fm/adchoices
Dr. Alanna Morris-Simon, Senior Medical Director for US Medical Affairs at Bayer, describes the symptoms and diagnostics used to classify heart failure and the key at-risk populations for this condition. The rapidly evolving landscape of heart failure treatments now includes the Bayer drug KERENDIA, a non-steroidal MRA approved to reduce cardiovascular death and heart failure in adults with an ejection fraction of 40% or more. This drug is part of an emerging trend to treat multiple related conditions simultaneously and could prevent the onset of heart failure and treat established heart failure. Alanna explains, "At a basic level, heart failure is a clinical syndrome, and that's important. I'm actually a heart failure cardiologist as well. And so this is important because patients have to have signs and symptoms. And those signs and symptoms really result from the heart being unable to either fill with blood properly or squeeze that blood out in a way that meets the body's demands. Either way, patients experience the same symptoms, and those include symptoms like swelling and weight gain, shortness of breath, either at rest or with activity, fatigue, abdominal swelling and bloating, loss of appetite, as well as other symptoms." "If a doctor or a clinician suspects a diagnosis of heart failure, 99.99% of the time, they'll start by ordering an echocardiogram or a heart ultrasound. Of course, the guidelines tell us to get a chest X-ray, get labs, those sorts of things. But really, we make the diagnosis for the most part based on the results of an echocardiogram because that echocardiogram allows us to visualize how the heart is pumping. It allows us to classify the type of heart failure so that if we see that the squeeze of the heart is impaired, we call that heart failure with reduced ejection fraction. And that's when the ejection fraction or EF is 40% or less. If the EF is in the 41 to 49% range, we classify that as heart failure with mildly reduced ejection fraction. And if patients have an ejection fraction of 50% or greater, we call that heart failure with preserved ejection fraction or HFpEF." "And we were excited that the FDA actually granted a priority review for KERENDIA because this really only occurs when the FDA recognizes that a treatment can fill a significant unmet need for a disease or a population of patients. And lo and behold, in July of 2025, finerenone was approved by the FDA under the trade name KERENDIA to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with an ejection fraction of 40% or more." #Bayer #Finerenone #Pharma #HeartFailure #HFpEF #HFmrEF #MRA #UnmetNeed #Cardiology #KERENDIA #FDA #CardiovascularHealth #MedicalBreakthrough #PatientCare #Innovation Bayer.com Download the transcript here
Dr. Alanna Morris-Simon, Senior Medical Director for US Medical Affairs at Bayer, describes the symptoms and diagnostics used to classify heart failure and the key at-risk populations for this condition. The rapidly evolving landscape of heart failure treatments now includes the Bayer drug KERENDIA, a non-steroidal MRA approved to reduce cardiovascular death and heart failure in adults with an ejection fraction of 40% or more. This drug is part of an emerging trend to treat multiple related conditions simultaneously and could prevent the onset of heart failure and treat established heart failure. Alanna explains, "At a basic level, heart failure is a clinical syndrome, and that's important. I'm actually a heart failure cardiologist as well. And so this is important because patients have to have signs and symptoms. And those signs and symptoms really result from the heart being unable to either fill with blood properly or squeeze that blood out in a way that meets the body's demands. Either way, patients experience the same symptoms, and those include symptoms like swelling and weight gain, shortness of breath, either at rest or with activity, fatigue, abdominal swelling and bloating, loss of appetite, as well as other symptoms." "If a doctor or a clinician suspects a diagnosis of heart failure, 99.99% of the time, they'll start by ordering an echocardiogram or a heart ultrasound. Of course, the guidelines tell us to get a chest X-ray, get labs, those sorts of things. But really, we make the diagnosis for the most part based on the results of an echocardiogram because that echocardiogram allows us to visualize how the heart is pumping. It allows us to classify the type of heart failure so that if we see that the squeeze of the heart is impaired, we call that heart failure with reduced ejection fraction. And that's when the ejection fraction or EF is 40% or less. If the EF is in the 41 to 49% range, we classify that as heart failure with mildly reduced ejection fraction. And if patients have an ejection fraction of 50% or greater, we call that heart failure with preserved ejection fraction or HFpEF." "And we were excited that the FDA actually granted a priority review for KERENDIA because this really only occurs when the FDA recognizes that a treatment can fill a significant unmet need for a disease or a population of patients. And lo and behold, in July of 2025, finerenone was approved by the FDA under the trade name KERENDIA to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with an ejection fraction of 40% or more." #Bayer #Finerenone #Pharma #HeartFailure #HFpEF #HFmrEF #MRA #UnmetNeed #Cardiology #KERENDIA #FDA #CardiovascularHealth #MedicalBreakthrough #PatientCare #Innovation Bayer.com Listen to the podcast here
In this finale, the gang has already taken out one of the human burglars, Larry. But Frank is made of different stuff. Apparently, he's come prepared and the sight of little folk attacking him doesn't seem to phase him too much. So what happens when 4 tiny beings take on a human burglar hellbent on either killing them or catching them? Find Out! The Cast: - Slone as Phil: https://www.tiktok.com/@slonerunning - Blackwell as Brabrex: https://linktr.ee/EveryMan95 - Spencer as Ekxander: https://linktr.ee/spenceydm - Taylor as Carl/Cam: https://linktr.ee/soyouwannabeadm Music is provided by Epidemic Sound Use our link for a 30-day Free Trial! https://share.epidemicsound.com/spf7rg/?playlist=pqqzqnqauplu95iie858kw85v7xnqexx Content Warnings: Violence, Bodily harm, Explicit Language, Drug and Alcohol use, Harm to animals (but 95% of animals are fully sentient people in this world), Claustrophobia, Bugs, Spiders. If we've missed anything, please let us know so that we can update our list. And remember to give us 5 Stars ⭐️⭐️⭐️⭐️⭐️ AND a positive review! This helps us so much, so tell your friends! We have VIDEO now! Subscribe to our YouTube to see the podcast! And other content! --------------------------- And CLICK HERE to find links to our Patreon, Discord, YouTube, Twitch, TikTok, Instagram, and more! Email us at Soyouwannabeadm@gmail.com WE HAVE MERCH! Click the link above!
Truth Nation: Case of Ryan Wedding - Episode 48 Welcome to Truth Nation! In episode 48, hosts Bill Bodner and retired Chief Mark Garrett delve into the intricate case of Ryan Wedding, a former Olympic snowboarder now dubbed by some as a modern-day Pablo Escobar of Canada. The episode explores Wedding's transition from an athlete to a major drug trafficker, his international drug smuggling operations, and his recent capture. The discussion examines the sensationalism in law enforcement narratives, the logistics of cocaine distribution from Mexico to Canada, and the gruesome murders ordered by the Wedding criminal enterprise. Additionally, the episode touches on the role of technology in modern drug trafficking and raises questions about the timing and nature of Wedding's surrender. Tune in for a deep dive into the complexities of this fascinating case.
In this raw and unforgettable episode, Virginia street legend Pretty Tony sits down to tell his life story — from being introduced to crack at a young age, to becoming one of the most prolific cocaine cooks in Virginia history, to growing up alongside future rap superstars like Pharrell and the Clipse. Pretty Tony breaks down how he perfected the infamous “mix” that made him the go-to hood chemist, what it was like cooking bricks in kitchens for kingpin-level dealers, and how violence, robberies, torture, and street politics shaped his reality as a teenager. He also shares near-death experiences, including being shot in the face, wild encounters with rip crews, and seeing close friends and family fall to the game. This episode dives deep into: -Learning to cook crack at a young age -Becoming the neighborhood “hood chef” -Growing up with Pharrell, Pusha T, and Malice -Virginia's hidden kingpin era -Drug droughts, cartel-style tactics, and street economics -Surviving shootouts, robberies, and betrayal A brutally honest look at the streets, the music, and the thin line between fame and prison. Go Support Tony! Book: https://a.co/d/036MGUqH Merch: https://shop.app/m/w53xak0gbe This Episode Is #Sponsored By The Following: Prizepicks! Visit https://prizepicks.onelink.me/LME0/CONNECT and use code CONNECT and get $50 in lineups when you play your first $5 lineup! Rocket Money! Let Rocket Money help you reach your financial goals faster. Join at https://rocketmoney.com/connect Join The Patreon For Bonus Content! https://www.patreon.com/theconnectshow 00:00 From the Trap House: Pretty Tony's Origins 06:35 Family Ties & Street Influence 13:33 Virginia's Crack Era: The Rise of the Street Game 21:05 This Episode Is Sponsored By PrizePicks 22:01 Family, Cousins, and Murderers 32:39 The Art of Cooking: Becoming the Hood Chef 40:03 Mastering the Mix: Cracking the Recipe 45:00 The Music Connection 47:24 This Episode Is Sponsored By Rocket Money 48:33 Links to Pharrell, Clipse, and the Scene 53:32 Hustling & Robbery Crews – The Risk and Respect 01:03:21 Rising Profits and Street Networking 01:16:31 High Stakes: Plug Connections & Expanding Operations 01:31:22 Caught in the Crosshairs: The Deadly Setup 01:46:09 Surviving the Hit: Aftermath and Transformation 01:55:00 Getting Out the Game & The Virginia Scene 02:01:47 Legacies, The Music Stardom, and Moving On 02:04:27 Reflecting on Regret, Survival & The Future Learn more about your ad choices. Visit podcastchoices.com/adchoices
Cop. Drug agent. Preacher. Marijuana activist. Cop buster. Can this really be one man? In their documentary “Never Get Busted”, David Anthony Ngo and Erin Williams-Weir follow the protean Barry Cooper. In this special interview recorded live late last year at the Hot Spring Documentary Film Festival (where our own Ken Jacobson serves as Executive Director), David and Erin share the lives, loves and ever-shifting mission of a man who despite constantly changing, continually seems rooted in an authentic calling. And they explore with him a legal system deeply compromised by misaligned incentives and financial corruption. Follow: @davidanthonyfilm & @nevergetbustedfilm on Instagram @topdocspod on X and Instagram The Presenting Sponsor of "Top Docs" is Netflix.
An unlikely partnership, Drug policy reformers and Second Amendment advocates team up in a case before the Supreme Court. Please Like, Comment and Follow 'Philip Teresi on KMJ' on all platforms: --- Philip Teresi on KMJ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. -- Philip Teresi on KMJ Weekdays 2-6 PM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Website | Facebook | Instagram | X | Podcast | Amazon | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.
This week on Carnival Cruising Podcastaways, Trevor, Jenn, and Thomas are back together and, thankfully, all survived another week without medical emergencies (hydration saves lives).The crew dives into Carnival's latest price increases, including changes to Bottomless Bubbles and gratuities, and debates whether four sodas a day is a lifestyle choice or a cry for help. Things escalate when they discuss a five-year-old Royal Caribbean cruiser with over 700 loyalty points, raising serious questions about gaming the system, suite math, and who is really in charge of the ship.They also cover:Drink packages, soda economics, and age discrimination (allegedly)Drug-sniffing dogs, port security horror stories, and thrift-store luggage mishapsBuild-A-Bear regret at seaParty cruises gone very wrongWhy you should never assume you'll remember repacking your bag with dignityIt's cruise news, questionable math, and classic Podcastaways banter—all in one voyage.
Today we're talking about a drug market that moved into a local affordable housing complex, as well as yet another surplus of unspent funds found in the city Housing Bureau's budget. Plus, a local psychiatrist's connection to the Epstein files, the Lake Oswego marquee that upset Amazon, and so much more. Joining host Claudia Meza on this week's Friday news roundup are Willamette Week reporter and author, Brianna Wheeler, and our very own senior producer, Giulia Fiaoni. Discussed in Today's Episode: A Drug Market Moves Into a Home Forward Apartment Building [Willamette Week] Portland Housing Bureau Finds at Least Another $15 Million in Unspent Funds [Portland Mercury] Lake Oswego Theater Loses Rights To Screen ‘Melania' After Marquee Jokes [Lake Oswego Review] Portland Lawmaker Pushes Tear Gas Ban After ICE Protest Crackdown [Oregonian] Prominent Portland Psychiatrist Corresponded With Jeffrey Epstein, Emails Show [Willamette Week] Become a member of City Cast Portland today! Get all the details and sign up here. Who would you like to hear on City Cast Portland? Shoot us an email at portland@citycast.fm, or leave us a voicemail at 503-208-5448. Want more Portland news? Then make sure to sign up for our morning newsletter and be sure to follow us on Instagram. Looking to advertise on City Cast Portland? Check out our options for podcast and newsletter ads at citycast.fm/advertise. Learn more about the sponsors of this February 6th episode: Oregon Ballet Neo Home Loans Pivot Portland
A new reward is on the table as investigators continue searching for Savannah Guthrie's mother. The ransom note deadline has passed, but authorities say they still have no suspect. Plus, the U.S. and Iran have quietly reopened indirect talks in Oman. The discussions are focused on Iran's nuclear program, but officials on both sides are signaling limits on how far negotiations can go. And President Donald Trump launches a cash-discount prescription site, pitching lower drug prices without insurance These stories and more highlight your Unbiased Updates for Friday, February 6, 2026.
Joyce talks about: The sacrifices of the US military and their families. Palm Beach County Supervisor of Elections office holding a contest where the winning design will be featured on the "I voted" sticker. votepalmbeach.govMidterm elections Dow spike Trump Rx website launched greatly reducing the prices on certain medications. Dems helping illegal criminal immigrations escape ICE.Human Trafficking and the Super Bowl.Derek from TMZ talks Savannah Guthrie ransom note, deadlines, Super Bowl and the halftime show, and Lil John's son found dead in pond. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Can a “miracle” weight-loss drug really slow aging? Guest host Cheryl Burke dives in with Dr. Jesse Mills to expose the shocking truth about GLP-1s, testosterone, sugar addiction, and the wellness myths doctors.See omnystudio.com/listener for privacy information.
Can a “miracle” weight-loss drug really slow aging? Guest host Cheryl Burke dives in with Dr. Jesse Mills to expose the shocking truth about GLP-1s, testosterone, sugar addiction, and the wellness myths doctors.See omnystudio.com/listener for privacy information.
First up on the podcast, host Sarah Crespi and Staff Writer Adrian Cho talk football and the latest science behind helmets engineered to reduce head injuries. Have better materials and testing led to fewer concussions and chronic traumatic encephalopathy in players? Next on the show, more than 100,000 people die from opioid overdoses in North America per year. Although much study has gone into addiction research, less attention has been paid to the biological details of overdose itself. John Strang, a professor in the National Addiction Centre at King's College London, joins the podcast to discuss the questions researchers could be asking about overdose, and how to partner with drug addicted people to find solutions. This week's episode was produced with help from Podigy. Learn more about your ad choices. Visit megaphone.fm/adchoices
Jennifer Rogers' story is a full-blown roller coaster—small-town “perfect life,” cheerleading and pageants, then addiction, meth dealing, custody loss, and a federal sentence that forced her to face everything she tried to outrun. In this episode, Jennifer opens up about the double life, the turning points, and the moment she finally realized: it's you vs. you.Now the founder of the National Women's Prison Reform Coalition, the visionary behind Rise Up Media, host of the Fenced In podcast, and author of The You Within, Jennifer shares what recovery really took, how she rebuilt her career through sales, and the spiritual shift that helped her reclaim her identity—and her life.Show sponsors: Navigating the challenges of white-collar crime? The White-Collar Support Group at Prisonist.org offers guidance, resources, and a community for those affected. Discover support today at Prisonist.org Protect your online reputation with Discoverability! Use code NIGHTMARE SUCCESS for an exclusive discount on services to boost your digital image and online reputation. Visit Discoverability.co and secure your online presence today. Skip the hassle of car shopping with Auto Plaza Direct. They'll handle every detail to find your perfect vehicle. Visit AutoPlazaDirect.com "Your personal car concierge!"
Can a “miracle” weight-loss drug really slow aging? Guest host Cheryl Burke dives in with Dr. Jesse Mills to expose the shocking truth about GLP-1s, testosterone, sugar addiction, and the wellness myths doctors.See omnystudio.com/listener for privacy information.
Can a “miracle” weight-loss drug really slow aging? Guest host Cheryl Burke dives in with Dr. Jesse Mills to expose the shocking truth about GLP-1s, testosterone, sugar addiction, and the wellness myths doctors.See omnystudio.com/listener for privacy information.
------------------- Watch This episode & more on YouTube! Connect With Us: @GoodMoms_BadChoices @TheGoodVibeRetreat @Good.GoodMedia @WatchErica @Milah_Mapp ------------------------------------------ PATREON Catch up with us over at Patreon and get all our Full visual episodes, bonus content & early episode releases. Submit your advice questions, anonymous secrets or vent about motherhood anonymously! Submit your questionsSee omnystudio.com/listener for privacy information.
Google parent company Alphabet on the move as the tech giant reports results. The details and numbers from their latest quarter, and why tech analyst Gene Munster sees the stock topping the Mag7 group this year. Plus Eli Lilly and Novo Nordisk heading in opposite directions as the weight loss drug race enters its next leg. Why one top health care analyst is flagging management confidence and pricing algorithms as the difference makers.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
When a son discovers that the man who raised him is capable of unimaginable harm, he is forced to become a whistleblower against his own father, risking his family, his identity, and everything he once believed to be true. Today's episode featured Kai Zen Bickle. To find out more about the legislation drafted with Child USA to close jurisdictional loopholes, specifically to ensure that evidence of sexual crimes committed against children on foreign soil can be brought back and used in U.S. courts, preventing perpetrators from escaping accountability by abusing international boundaries, please visit: https://childusa.org/law/ Producers: Whit Missildine, Andrew Waits, Jason Blalock Content/Trigger Warnings: Child sexual abuse, Sexual assault, Rape, Statutory rape, Grooming, Drug-facilitated sexual assault, Incest (sexual exploitation by a parent), Emotional abuse, Gaslighting, Psychological manipulation, Sexual exploitation, Coercion, Trauma, Dissociation, Moral injury, Whistleblower retaliation, Family betrayal, explicit language Social Media:Instagram: @actuallyhappeningTwitter: @TIAHPodcast Website: thisisactuallyhappening.com Website for Andrew Waits: andrdewwaits.comWebsite for Jason Blalock: jasonblalock.com Support the Show: Support The Show on Patreon: patreon.com/happening Wondery Plus: All episodes of the show prior to episode #130 are now part of the Wondery Plus premium service. To access the full catalog of episodes, and get all episodes ad free, sign up for Wondery Plus at wondery.com/plus Shop at the Store: The This Is Actually Happening online store is now officially open. Follow this link: thisisactuallyhappening.com/shop to access branded t-shirts, posters, stickers and more from the shop. Transcripts: Full transcripts of each episode are now available on the website, thisisactuallyhappening.com Intro Music: “Sleep Paralysis” - Scott VelasquezMusic Bed: Music To Air (MTA) - Houses ServicesIf you or someone you know is struggling with the effects of trauma or mental illness, please refer to the following resources: National Suicide and Crisis Lifeline: Text or Call 988 National Alliance on Mental Illness: 1-800-950-6264National Sexual Assault Hotline (RAINN): 1-800-656-HOPE (4673) See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Covino & Rich are broadcasting live from Radio Row in San Francisco for Super Bowl 60! The guys react to ex-NFL star Tyrann Mathieu’s attempt to use bleach to pass a college drug test. Then, Fox Sports Radio’s own Rob Parker from The Odd Couple joins the show in Hour 2!See omnystudio.com/listener for privacy information.
© 2020-2026 Ivy Podcast Discovery LLC
